BIBAX
LIVE

Serial Number

97766160

Owner

de la Rosa, Kathrin

Attorney

Nicholas D. Wells

Filing Date

Jan 24, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BIBAX Trademark

Serial Number: 97766160

BIBAX is a trademark filed by de la Rosa, Kathrin on January 24, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

de la Rosa, Kathrin

Kopenhagener Str. 23
Berlin D-10437 , DE

Entity Type: 01

Trademark Details

Filing Date

January 24, 2023

Registration Date

Not Registered

Goods & Services

Provision of information and data in the field of medical and veterinary research and development, namely, in the fields of immunology, infectiology and vaccines; research and design for the pharmaceutical industry, namely in the fields of immunology, infectiology and vaccines; biomedical research services; research and development in the field of vaccines; software development and research in the fields of infectiology and immunology; research and development of biomolecules, cells and cell products for medical purposes; research and development of biomedical goods, in particular therapeutic and prophylactic substances, namely, pharmaceuticals for medical purposes, and preparations for the treatment of Coronaviridae, including SARS-CoV-2 and MERS-CoV, Flaviviridae including Dengue, hepatitis, yellow fever, and Zika virus, Herpesviridae including EBV, Orthomyxoviridae including Influenzaviruses, and Filoviridae; medical laboratory services; computer diagnostic services

Medical and veterinary preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment and prevention of human infectious diseases; biomedical pharmaceutical products for the treatment and prevention of human infectious diseases; clinical diagnostic reagents; therapeutic agents being Therapeutic vaccines; prophylactical agent substances, namely, pharmaceutical preparations for the prevention of infectious diseases; medicine being Medicinal preparations for the treatment of infectious diseases and for use in; biological and chemical reagents, for medical and veterinary uses; agonists for medical and veterinary uses, namely, namely, pharmaceutical preparations for the treatment and prevention of human infectious diseases; medicines for veterinary purposes for the treatment and prevention of infectious diseases; amino acids for medical or veterinary purposes; antibacterial pharmaceuticals; anti-bacterial preparations; antibacterial substances for medical purposes; antigens, namely, pharmaceutical preparations for the treatment and prevention of infectious diseases; antibodies, namely, monoclonal antibodies for in vivo or clinical use; antitoxins; antiviral drugs for treating influenza; antiviral drugs for treating hiv; anti-viral agents, namely, anti-viral antigens being pharmaceutical preparations for the treatment and prevention of infectious diseases; autoantigens, namely, pharmaceutical preparations for the treatment and prevention of human autoimmune diseases and cancer; biological adjuvants for medical purposes; endogenous antigens, namely, pharmaceutical preparations for the treatment and prevention of human autoimmune diseases and cancer; exogenous antigens, namely, pharmaceutical preparations for the treatment and prevention of infectious diseases; human immune globulin for the treatment and prevention of cancer and infectious diseases; human vaccine preparations; immunomodulators; immunostimulants; vaccines against flu; immunotherapeutic agents for bacterial infections; anti-infective goods for medical and veterinary uses; medicated mouth spray; medicated nasal spray preparations; anti-malarials; neoantigens, namely, pharmaceutical preparations for the treatment and prevention of cancer; pharmaceutical products for treating respiratory diseases, pharmaceutical products for the treatment of infectious diseases, pharmaceutical preparations for the treatment of autoimmune disorders, pharmaceutical preparations for the treatment of disorders caused by bacteria, pharmaceutical preparations for the treatment of diseases caused by bacteria, pharmaceutical preparations for the treatment of autoimmune disorders, pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention of diseases caused by bacteria; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of disorders of the immune system; anti-infectives; anti- tuberculous preparations; tumour antigens, namely, pharmaceutical preparations for the treatment and prevention of cancer; viral antigens, namely, pharmaceutical preparations for the treatment and prevention of infectious diseases; viral vaccines; veterinary vaccines; vaccines; mrna and vector-based vaccines; protein-based vaccines

Filing History

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 16, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 16, 2025 GNSL
SUSPENSION LETTER WRITTEN
Dec 16, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 16, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 16, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Nov 10, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Sep 9, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Sep 9, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Sep 9, 2025 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Aug 6, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 4, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 4, 2025 GNSL
SUSPENSION LETTER WRITTEN
Feb 4, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 3, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 3, 2025 CRFA
ASSIGNED TO LIE
Feb 3, 2025 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jan 31, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 13, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 13, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 13, 2025 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jan 10, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 31, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 31, 2024 GNSL
SUSPENSION LETTER WRITTEN
Jan 31, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 26, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 25, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 25, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 25, 2023 GNRN
NON-FINAL ACTION E-MAILED
Oct 25, 2023 GNRT
NON-FINAL ACTION WRITTEN
Oct 25, 2023 CNRT
ASSIGNED TO EXAMINER
Oct 21, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 13, 2023 NWOS
NEW APPLICATION ENTERED
Jan 27, 2023 NWAP